We are live on ! Find out more
BCLI

BRAINSTORM CELL THERAPUTC
BCLI

Delisted

BCLI was delisted on the 17th of July, 2025.

Back to rankings

48 hedge funds and large institutions have $11M invested in BRAINSTORM CELL THERAPUTC in 2022 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 6 increasing their positions, 17 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

694% more call options, than puts

Call options by funds: $2.45M | Put options by funds: $308K

450% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 2

23% more funds holding

Funds holding: 39 → 48 (+9)

0.04% less ownership

Funds ownership: 0.76% → 0.73% (-0.04%)

28% less capital invested

Capital invested by funds: $15.3M → $11M (-$4.3M)

65% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 17

Holders
48
Holders Change
+9
Holders Change %
+23.08%
% of All Funds
0.81%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
6
Reduced
17
Closed
2
Calls
$2.45M
Puts
$308K
Net Calls
+$2.14M
Net Calls Change
+$1.16M

Top Buyers

Rank Fund Capital Flow
1
LWM
Liberty Wealth Management
California
+$90.1K
2
VF
Virtu Financial
New York
+$62.1K
3
Renaissance Technologies
Renaissance Technologies
New York
+$51.3K
4
Jane Street
Jane Street
New York
+$36.3K
5
SCFS
S.C. Financial Services
Arizona
+$30.6K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$238K
2
JP Morgan Chase
JP Morgan Chase
New York
-$178K
3
IC
Ikarian Capital
Texas
-$152K
4
Millennium Management
Millennium Management
New York
-$93.8K
5
WCG
Weaver Consulting Group
California
-$76.1K
Name Holding Trade Value Shares
Change 		Change in
Stake
Jane Street
26
Jane Street
New York
$33K +$36.3K +806 New
Bank of New York Mellon
27
Bank of New York Mellon
New York
$32K -$2.16K -48 -6%
RJFSA
28
Raymond James Financial Services Advisors
Florida
$32K -$856 -19 -2%
Charles Schwab
29
Charles Schwab
California
$32K – – –
Osaic Holdings
30
Osaic Holdings
Arizona
$31K – – –
ACA
31
Aptus Capital Advisors
Alabama
$28K -$6.84K -152 -18%
UBS Group
32
UBS Group
Switzerland
$22K +$270 +6 +1%
Bank of America
33
Bank of America
North Carolina
$21K +$1.17K +26 +5%
SPIA
34
Steward Partners Investment Advisory
New York
$18K -$2.97K -66 -13%
TRCT
35
Tower Research Capital (TRC)
New York
$15K +$16.7K +370 New
BSB
36
Bangor Savings Bank
Maine
$11K +$12K +267 New
IFAM
37
Institutional & Family Asset Management
Colorado
$8K – – –
WT
38
Washington Trust
Rhode Island
$7K – – –
HI
39
Harbour Investments
Wisconsin
$7K +$7.93K +176 New
Royal Bank of Canada
40
Royal Bank of Canada
Ontario, Canada
$4K – – –
CCMW
41
Cypress Capital Management (Wyoming)
Wyoming
$3K +$3.02K +67 New
BNP Paribas Financial Markets
42
BNP Paribas Financial Markets
France
$1K -$360 -8 -25%
First Manhattan
43
First Manhattan
New York
$1K – – –
CG
44
CFO4Life Group
Texas
– -$40K -800 Closed
Two Sigma Advisers
45
Two Sigma Advisers
New York
– -$37K -733 Closed
Simplex Trading
46
Simplex Trading
Illinois
– -$6.58K -146 -92%
Fidelity Investments
47
Fidelity Investments
Massachusetts
– +$90 +2 New
CA
48
CoreCap Advisors
Michigan
– +$405 +9 New
1
2

BCLI Hedge Fund Activity: Q2 2022 in Review

48 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q2 2022, worth a combined $11M — down 28% from $15.3M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new BCLI positions and 2 closed out — a net gain of 9 holders — while 6 added to existing stakes and 17 trimmed.

The largest buyer was Liberty Wealth Management, opening a new position worth an estimated $90.1K. The largest seller was Susquehanna International Group, cutting an estimated $238K.

  • 48 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q2 2022, up from 39 in Q1 2022.
  • Funds reported $11M of BRAINSTORM CELL THERAPUTC stock for Q2 2022, down 28% quarter-over-quarter.
  • 11 funds opened new BRAINSTORM CELL THERAPUTC positions in Q2 2022 and 2 closed out, a net change of +9 holders.
  • The largest BRAINSTORM CELL THERAPUTC buyer in Q2 2022 was Liberty Wealth Management, an estimated $90.1K added.
  • The largest BRAINSTORM CELL THERAPUTC seller in Q2 2022 was Susquehanna International Group, an estimated $238K sold.

Based on aggregated 13F filings for Q2 2022.